Provider: Wright Reports
Bavarian Nordic A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bavarian Nordic A/S Maintains FY 2013 Guidance-Ritzau
Ritzau reported that Bavarian Nordic A/S announced that the Company's fiscal year 2013 financial guidance remains unchanged. The Company continues to expect fiscal year 2013 revenues in the level of DKK 1,100 million and a break-even result before tax. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of DKK 1,115.07 million for the fiscal year 2013.
Latest Developments for Bavarian Nordic A/S
Latest Key Developments in Pharmaceuticals
- Alimera Sciences' Iluvien receives marketing authorization in Norway for the treatment of chronic diabetic macular edema
- AB Science announces publication of results from randomized phase 2 study of masitinib
- R&I affirms Eisai Co Ltd's rating at "AA-" and announces negative outlook
- Retrophin Inc proposes acquisition of Clinuvel Pharmaceuticals
- Share this
- Digg this